allogene
A Senior Director at Allogene Therapeutics leads a cross-functional program team to manage the development and execution of program strategy in alignment with corporate goals. The role involves managing program scope, timelines, deliverables, budget, risks, decisions, and communications.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2017
Allogene is a clinical-stage biotechnology company developing off-the-shelf AlloCAR T cell therapies using multiplex gene engineering and gene-editing to create allogeneic (ready-made) CAR T candidates. The company pairs a proprietary lymphodepletion approach with scalable, state-of-the-art manufacturing to optimize safety, durability, and broader patient access. Lead programs include cemacabtagene ansegedleucel (cema‑cel) for large B‑cell lymphoma (including frontline DLBCL), ALLO‑316 for renal cell carcinoma, and ALLO‑329 for autoimmune disease, alongside a broader pipeline. Allogene’s platform strategy aims to accelerate delivery of cell therapies by removing patient-specific manufacturing constraints.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for allogene.
80% above the average for this role
Associate Director/Director, Clinical Program Management
Skyhawk Therapeutics
Director, Program Management, Neuroscience
Bristol Myers Squibb
Associate Director, Global Program Management
Sarepta Therapeutics
Associate Director, Program Management
Structure Therapeutics
Director, Program Management
White-Horse-224
Program/Project Management Lead
Accenture